2018
Ventricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014
Goldsweig AM, Wang Y, Forrest JK, Cleman MW, Minges KE, Mangi AA, Aronow HD, Krumholz HM, Curtis JP. Ventricular septal rupture complicating acute myocardial infarction: Incidence, treatment, and outcomes among medicare beneficiaries 1999–2014. Catheterization And Cardiovascular Interventions 2018, 92: 1104-1115. PMID: 29513365, DOI: 10.1002/ccd.27576.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionVentricular septal ruptureTimely primary PCIMortality ratePrimary PCIPercutaneous repairSeptal ruptureMyocardial infarctionRetrospective cohort studyUnadjusted mortality ratesUnrepaired patientsVSR repairFatal complicationCohort studyAnnual incidenceMedicare feeService beneficiariesPatientsIncidenceStudy periodMortalityHospitalizationInfarctionRepairPCI
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2004
Management of implantable cardioverter defibrillators in end-of-life care.
Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Annals Of Internal Medicine 2004, 141: 835-8. PMID: 15583224, DOI: 10.7326/0003-4819-141-11-200412070-00006.Peer-Reviewed Original Research
2002
Depression and Risk of Heart Failure Among the Elderly: A Prospective Community-Based Study
Williams SA, Kasl SV, Heiat A, Abramson JL, Krumholz HM, Vaccarino V. Depression and Risk of Heart Failure Among the Elderly: A Prospective Community-Based Study. Psychosomatic Medicine 2002, 64: 6-12. PMID: 11818580, DOI: 10.1097/00006842-200201000-00002.Peer-Reviewed Original ResearchConceptsHeart failureIndependent risk factorCoronary heart diseaseImpact of depressionEffect of depressionHospital admissionComorbidity factorsCox regressionProspective CommunityElderly menFunctional statusHeart diseaseRisk factorsElderly womenBaseline differencesEpidemiological studiesFunctional limitationsGreater riskUnderlying causeDepressionIncidenceEstablished PopulationsCommunity sampleDepressed participantsWomen
1996
Epidemiologic and economic impact of advanced heart failure
Funk M, Krumholz H. Epidemiologic and economic impact of advanced heart failure. The Journal Of Cardiovascular Nursing 1996, 10: 1-10. PMID: 8656234, DOI: 10.1097/00005082-199601000-00002.Peer-Reviewed Original ResearchConceptsHeart failureMajor public health problemAdvanced heart failureCoronary heart diseasePublic health problemFinal common pathwayHeart diseaseRisk factorsCardiovascular diseaseCardiovascular conditionsHealth problemsPremature deathLethal conditionCommon pathwayPrevalenceDiseaseIncidenceNumber of peopleFailureEconomic impactPrognosisMortality